Protein Biomarkers of Lung Cancer Risk Among Individuals Who Never Smoked
4 affiliations
- 1International Agency for Research on Cancer/World Health Organization (IARC/WHO), Lyon, France
- 2Department of Population Science, American Cancer Society, Atlanta, Georgia
- 3Epidemiology Program, University of Hawaiʻi Cancer Center, Honolulu
- 4Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee
Abstract
Importance: Approximately one-quarter of lung cancers occur in people who never smoked (PWNS). For smoking-associated lung cancer, blood-based protein biomarkers can improve risk assessment.
Objective: To identify protein biomarkers for lung cancer among PWNS.
Design, Setting, and Participants: This nested case-control study from 4 cohorts in the Lung Cancer Cohort Consortium (LC3) was conducted for discovery to identify proteins, and a cohort study was conducted using data in the UK Biobank for replication. Participants were from the US, China, and the United Kingdom and donated blood samples between 1996 and 2010. Lung cancer case-control pairs of PWNS from 4 cohorts in the LC3 were matched by cohort, age, sex, and blood collection date. In addition, 49 291 participants in the UK Biobank were included. Data were analyzed from March 2024 to May 2025.
Exposure: A total of 2821 circulating proteins measured in prediagnostic blood samples collected up to 5 years before lung cancer diagnosis for cases.
Main Outcomes and Measures: Primary measures were odds ratios (ORs) for discovery and hazard ratios (HRs) for replication.
Results: Among 180 case-control pairs of PWNS (360 participants) in the 4 LC3 cohorts, 256 participants (71.1%) were female, and the median (IQR) age at enrollment was 66 (55-70) years. In LC3, using a false discovery rate–adjusted P value threshold of .05, 2 proteins were identified as being associated with lung cancer among PWNS: carcinoembryonic antigen–related cell adhesion molecule 5 (CEACAM5) (OR, 1.65 [95% CI, 1.31-2.09]) and CEACAM6 (OR, 1.72 [95% CI, 1.33-2.22]). Associations for both proteins were successfully replicated among participants analyzed regardless of smoking history across 5 years of follow-up in the UK Biobank (CEACAM5: HR, 1.92 [95% CI, 1.66-2.22]; CEACAM6: HR, 1.86 [95% CI,1.59-2.16]). The correlation between CEACAM5 and CEACAM6 was weak (Pearson ρ = 0.25 in the LC3); therefore, both proteins maintained associations with high relative risks after mutual adjustment. For 36 proteins previously identified as robust markers of smoking-related lung cancer, most showed no evidence of an association among PWNS (median OR, 1.47 [IQR, 1.38-1.61] vs 1.01 [IQR, 0.94-1.13] in smoking-related vs nonsmoking lung cancer).
Conclusions and Relevance: In this nested case-control study, 2 proteins were identified, CEACAM5 and CEACAM6, that were associated with lung cancer in PWNS. Larger studies are needed to evaluate whether there are additional biomarkers associated with lung cancer in PWNS and whether they can identify PWNS with high lung cancer risk.
Related
- Risk-Based Lung Cancer Screening for People Who Never Smoked
- Real-world outcomes of induction chemoimmunotherapy in patients with non-small cell lung cancer who have never smoked.
- Identification and validation of RNA-binding protein-associated biomarkers in esophageal cancer
- Healthcare Inequities and Structural Racism as Determinants of Treatment and Survival among Individuals Recently Diagnosed with Cervical Cancer from Two Diverse Population-Based Cancer Registries: The ACHIEVE Study
- Cancer risk among individuals with mental illness - a systematic review and meta-analysis of nordic register-based prospective studies.
BibTeX
@article{zahed2026protein,
title = {{Protein Biomarkers of Lung Cancer Risk Among Individuals Who Never Smoked}},
author = {Hana Zahed and Connie Bulos-Salim and Karine Alcala and Shaymaa AlWaheidi and Xiaoshuang Feng and Ying Wang and Alpa V. Patel and Loïc Le Marchand and Wei Zheng and Xiao-Ou Shu and Mattias Johansson and Hilary A. Robbins},
journal = {JAMA Network Open},
year = {2026},
month = nov,
doi = {10.1001/jamanetworkopen.2026.41494},
url = {https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2856147},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Protein Biomarkers of Lung Cancer Risk Among Individuals Who Never Smoked
AU - Hana Zahed
AU - Connie Bulos-Salim
AU - Karine Alcala
AU - Shaymaa AlWaheidi
AU - Xiaoshuang Feng
AU - Ying Wang
AU - Alpa V. Patel
AU - Loïc Le Marchand
AU - Wei Zheng
AU - Xiao-Ou Shu
AU - Mattias Johansson
AU - Hilary A. Robbins
PY - 2026
DA - 2026/11/02
JO - JAMA Network Open
DO - 10.1001/jamanetworkopen.2026.41494
UR - https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2856147
AB - Importance: Approximately one-quarter of lung cancers occur in people who never smoked (PWNS). For smoking-associated lung cancer, blood-based protein biomarkers can improve risk assessment. Objective: To identify protein biomarkers for lung cancer among PWNS. Design, Setting, and Participants: This nested case-control study from 4 cohorts in the Lung Cancer Cohort Consortium (LC3) was conducted for discovery to identify proteins, and a cohort study was conducted using data in the UK Biobank for replication. Participants were from the US, China, and the United Kingdom and donated blood samples between 1996 and 2010. Lung cancer case-control pairs of PWNS from 4 cohorts in the LC3 were matched by cohort, age, sex, and blood collection date. In addition, 49 291 participants in the UK Biobank were included. Data were analyzed from March 2024 to May 2025. Exposure: A total of 2821 circulating proteins measured in prediagnostic blood samples collected up to 5 years before lung cancer diagnosis for cases. Main Outcomes and Measures: Primary measures were odds ratios (ORs) for discovery and hazard ratios (HRs) for replication. Results: Among 180 case-control pairs of PWNS (360 participants) in the 4 LC3 cohorts, 256 participants (71.1%) were female, and the median (IQR) age at enrollment was 66 (55-70) years. In LC3, using a false discovery rate–adjusted P value threshold of .05, 2 proteins were identified as being associated with lung cancer among PWNS: carcinoembryonic antigen–related cell adhesion molecule 5 (CEACAM5) (OR, 1.65 [95% CI, 1.31-2.09]) and CEACAM6 (OR, 1.72 [95% CI, 1.33-2.22]). Associations for both proteins were successfully replicated among participants analyzed regardless of smoking history across 5 years of follow-up in the UK Biobank (CEACAM5: HR, 1.92 [95% CI, 1.66-2.22]; CEACAM6: HR, 1.86 [95% CI,1.59-2.16]). The correlation between CEACAM5 and CEACAM6 was weak (Pearson ρ = 0.25 in the LC3); therefore, both proteins maintained associations with high relative risks after mutual adjustment. For 36 proteins previously identified as robust markers of smoking-related lung cancer, most showed no evidence of an association among PWNS (median OR, 1.47 [IQR, 1.38-1.61] vs 1.01 [IQR, 0.94-1.13] in smoking-related vs nonsmoking lung cancer). Conclusions and Relevance: In this nested case-control study, 2 proteins were identified, CEACAM5 and CEACAM6, that were associated with lung cancer in PWNS. Larger studies are needed to evaluate whether there are additional biomarkers associated with lung cancer in PWNS and whether they can identify PWNS with high lung cancer risk.
SN - 2574-3805
ER -